New Drugs Archives | Surviving Mesothelioma

New Biomarker Could Help Eradicate Mesothelioma Resistance to Chemotherapy

Researchers in the Netherlands have unveiled what may be a major breakthrough in the chemotherapeutic treatment of malignant mesothelioma. Malignant mesothelioma, a rare and virulent cancer caused by asbestos exposure, is notoriously resistant to standard cancer treatments, including chemotherapy. Even the only chemotherapy drug specifically approved for the treatment of mesothelioma, Alimta (pemetrexed), only works for some patients. Now, a new study published in the … Continue reading New Biomarker Could Help Eradicate Mesothelioma Resistance to Chemotherapy »

Curcumin Shrinks Aggressive Mesothelioma Tumors in New Study

The bright yellow chemical that gives turmeric its spicy kick has scored yet another win as a possible treatment for malignant mesothelioma. This time, scientists used it on lab rats to successfully shrink one of the most aggressive types of mesothelioma tumors. The plant polyphenol curcumin has been the subject of numerous malignant mesothelioma studies in recent years, in part because of its powerful anti-inflammatory properties. Curcumin as … Continue reading Curcumin Shrinks Aggressive Mesothelioma Tumors in New Study »

New Chemotherapy Booster May Extend Mesothelioma Survival

Cancer researchers say the VEGF-inhibitor nintedanib (Ofev) extended mesothelioma survival by more than five months in patients on standard chemotherapy in a new trial. That is among the findings of a recently-published Phase II study of nintedanib as an adjunct therapy to pemetrexed (Alimta) and cisplatin for malignant pleural mesothelioma. Nintedanib Trial Details Nintedanib is currently used to treat idiopathic pulmonary fibrosis and some types … Continue reading New Chemotherapy Booster May Extend Mesothelioma Survival »

Using Immune Cells to Predict Mesothelioma Outcomes

Immune system cells may be some of the best predictors of mesothelioma outcomes, according to a group of British scientists. A new article in the British Journal of Cancer has found a close association between outcomes in people with different subtypes of malignant mesothelioma and the levels of different types of immune system cells in their bodies. Measuring Immune Response To create the experiment, researchers … Continue reading Using Immune Cells to Predict Mesothelioma Outcomes »

Long-Term Peritoneal Mesothelioma Survival with Apitolisib

There is hopeful news this week about the survivability of peritoneal mesothelioma, particularly when relapses are treated with a powerful drug called apitolisib. Peritoneal mesothelioma is a less common form of the rare asbestos-related cancer, malignant mesothelioma. It starts on the membrane that surround the abdominal organs and can quickly spread throughout the abdomen. According to the National Cancer Institute, the one-year survival rates for … Continue reading Long-Term Peritoneal Mesothelioma Survival with Apitolisib »

Antibody-Drug Conjugate Fails to Stop Recurrent Pleural Mesothelioma

A new drug designed to treat recurrent malignant mesothelioma while minimizing side effects has failed to meet expectations. Anetumab ravtansine, is an antibody-drug conjugate (ADC) developed with biotechnology firms ImmunoGen and MorphoSys and owned by Bayer.  It had been the focus of a Phase II clinical trial for pleural mesothelioma. The trial has now been stopped. Understanding ADCs Many of the most dangerous side effects of … Continue reading Antibody-Drug Conjugate Fails to Stop Recurrent Pleural Mesothelioma »

Second-Line Immunotherapy Treatment Fails to Improve Mesothelioma Survival

A large international clinical trial of the immunotherapy drug tremelimumab as a second- or third-line treatment option for malignant mesothelioma has produced some disappointing news. Drug maker AstraZeneca has just released an update on the ongoing DETERMINE trial which suggests that the survival rates are roughly the same for previously-treated mesothelioma patients whether they later received treatment with tremelimumab or a placebo. What is Tremelimumab? … Continue reading Second-Line Immunotherapy Treatment Fails to Improve Mesothelioma Survival »

Study to Test New Three-Drug Treatment for Pleural Mesothelioma

The makers of a VEGF-inhibitor called nintedanib are recruiting patients with unresectable pleural mesothelioma for a Phase III clinical trial of the drug in combination with standard chemotherapy. The multicenter trial sponsored by drug maker Boehringer Ingelheim will eventually include a total of 450 mesothelioma patients, but preliminary results from the first 87 patients look promising.  According to data presented at the 2017 American Society of Clinical Oncology … Continue reading Study to Test New Three-Drug Treatment for Pleural Mesothelioma »

Chamomile Tea May Hold the Secret to Longer Mesothelioma Survival

A new study suggests that a flavonoid found in parsley, celery, and chamomile tea may help improve the odds of surviving malignant mesothelioma. Scientists in Italy have just released some promising findings from tests of the compound apigenin on mesothelioma cells in the lab and in live mice. What is Apigenin? Apigenin is a plant pigment that is part of a larger group of chemicals … Continue reading Chamomile Tea May Hold the Secret to Longer Mesothelioma Survival »

Osteoporosis Drug May Help Treat Advanced Mesothelioma, Too

A drug normally used to treat and prevent osteoporosis may be useful in the treatment of advanced malignant mesothelioma, too. The drug, called zoledronic acid, is a member of the drug class bisphosphonates and is also used to prevent skeletal fractures in patients with certain kinds of cancer.   In a new study published in the journal Lung Cancer, University of Alabama researchers found that more than … Continue reading Osteoporosis Drug May Help Treat Advanced Mesothelioma, Too »

Get your free copy of
“Surviving Mesothelioma” Today!